ScholarIQanswers from OpenAlex
Integral Consulting (United States)
InstitutionResearch output, impact & collaborations
Integral Consulting (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Integral Consulting (United States)?
ScholarIQrecord summary
Integral Consulting (United States) is a research organisation in Seattle, US. OpenAlex records 2,774 works and 21,961 citations for it. 1,192 researchers list it as their most recent affiliation.
How many works does Integral Consulting (United States) have?
ScholarIQindexed works
Integral Consulting (United States) has 2,774 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Integral Consulting (United States) have?
ScholarIQcitation count
Integral Consulting (United States) has 21,961 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Integral Consulting (United States)?
ScholarIQresearcher count
Integral Consulting (United States) has 1,192 researchers in the ScholarIQ index.
What is the average h-index at Integral Consulting (United States)?
ScholarIQavg h-index
Integral Consulting (United States) has an average h-index of 60 in OpenAlex.
What is the ROR of Integral Consulting (United States)?
ScholarIQror
The ROR for Integral Consulting (United States) is on the source record.
What is the OpenAlex record for Integral Consulting (United States)?
ScholarIQopenalex
The OpenAlex for Integral Consulting (United States) is on the source record.
Who are the most-cited researchers behind Integral Consulting (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Integral Consulting (United States)?
ScholarIQmost cited works
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky, Lisa A. Beck, Andrew Blauvelt, Michael J. Cork, Jonathan I. Silverberg, Mette Deleuran, Yoko Kataoka, J.‐P. Lacour, Külli Kingo, Margitta Worm, Yves Poulin, Andreas Wollenberg, Yuhwen Soo, Neil M.H. Graham, Gianluca Pirozzi, Bolanle Akinlade, Heribert Staudinger, Vera Mastey, Laurent Eckert, Abhijit Gadkari, Neil Stahl, George D. Yancopoulos, Marius Ardeleanu
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez
How much of the research on Integral Consulting (United States) is open access?
ScholarIQopen access share
67%OPEN ACCESS